Artificial intelligence-enhanced risk stratification of chemotherapy or immunotherapy-related cardiotoxicity using electrocardiographic images

Evangelos K. Oikonomou MD DPhil[a], Veer Sangha BS[a,b], Lovedeep S. Dhingra MBBS[a], AryaAminorroaya MD MPH[a], Andreas Coppi PhD[c], Harlan M. Krumholz MD SM[a,c], Lauren A. Baldassarre MD [a], Rohan Khera MD MS[a,c,d,e*]

[a] Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
[b] Department of Engineering Science, University of Oxford, Oxford, UK
[c] Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, USA
[d] Section of Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, CT, USA
[e] Section of Health Informatics, Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA

Brief title: AI-ECG-guided cardiotoxicity monitoring in chemotherapy and immunotherapy

Word count: 3257 words
Figures: 7
Tables: 1

Disclosures: R.K. is an Associate Editor of JAMA and receives research support, through Yale, from the Blavatnik Foundation, Bristol-Myers Squibb, Novo Nordisk, and BridgeBio. He is a coinventor of U.S. Provisional Patent Applications 63/177,117, 63/428,569, 63/346,610, 63/484,426, and 63/508,315, and a co-founder of Ensight-AI, Inc. R.K. and E.K.O. are co-founders of Evidence2Health, a health analytics company. E.K.O. is a co-inventor in patent applications (US17/720,068, 63/619,241, 63/177,117, 63/580,137, 63/606,203, 63/619,241, WO2018078395A1, WO2020058713A1), has been an ad hoc consultant for Caristo Diagnostics, Ltd, and has received royalty fees from technology licensed through the University of Oxford. H.M.K. works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs, was a recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Martin Baughman Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a member of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the co-founder of Hugo Health, a personal health information platform, and co-founder of Refactor Health, a healthcare AI-augmented data management company, and Ensight-AI, Inc. All other authors declare no competing interests.

[*]Corresponding author:
Rohan Khera, MD, MS
195 Church St, 6th Floor, New Haven, CT 06510
203-764-5885; rohan.khera@yale.edu; @rohan_khera

ABSTRACT (283 words)

Background: Risk stratification strategies for cancer therapeutics-related cardiac dysfunction (CTRCD) rely on serial monitoring by specialized imaging, limiting their scalability and affordability.

Objectives: To examine an artificial intelligence (AI)-enhanced electrocardiographic (AI-ECG) surrogate for imaging-based risk biomarkers, and its association with CTRCD.

Methods: Across five hospitals of a U.S.-based health system (2013-2023), we identified patients with breast cancer or non-Hodgkin lymphoma (NHL) who received anthracyclines (AC) and/or trastuzumab (TZM), as well as a (negative) control cohort of patients receiving immune checkpoint inhibitors (ICI). We deployed a validated AI model of left ventricular systolic dysfunction (LVSD) to ECG images (≥0.1, positive screen) and explored the association between the model's predictions and: i) global longitudinal strain (GLS) measurements within 15 days; ii) future CTRCD (new cardiomyopathy, heart failure, or left ventricular ejection fraction (LVEF) decrease to <50%), and LVEF decrease <40%. In a negative control analysis of patients receiving ICI, we correlated baseline AI-ECG LVSD predictions with downstream myocarditis.

Results: Higher AI-ECG LVSD predictions were associated with progressively worse GLS (-18% [IQR: -20 to -17%] for AI-ECG predictions <0.1, to -12% [-15 to -9%] for ≥0.5 (p<0.001), n=7,271). In 1,308 patients receiving AC/TZM (age 59 [IQR 49-67] years, 999 [76.4%] women, 80 [IQR 42-115] follow-up months) a positive baseline AI-ECG LVSD screen was associated with ~2-fold and ~4.8-fold increase in the incidence of CTRCD ($HR_{adjusted}$ 2.22 [95%CI: 1.63-3.02]), and LVEF <40% ($HR_{adjusted}$ 4.76 [95%CI: 2.62-8.66], p<0.001), respectively. Among 2,056 patients receiving ICI (age 65 [IQR 57-73] years, 913 (44.4%) women, follow-up 63 [IQR 28-99] months) AI-ECG predictions were not associated with ICI myocarditis risk ($HR_{adjusted}$ 1.36 [0.47-3.93]).

Conclusion: AI applied to baseline ECG images can stratify the risk of CTRCD associated with anthracycline or trastuzumab exposure.

CONDENSED ABSTRACT (87 words)

There is an unmet need for scalable and affordable biomarkers to stratify the risk of cancer therapeutics-related cardiac dysfunction (CTRCD). In this hospital system-based, decade-long cohort of patients without cardiomyopathy receiving anthracyclines or trastuzumab, a validated artificial intelligence algorithm applied to baseline electrocardiographic (AI-ECG) images identified individuals with a 2-fold and 4.8-fold risk of developing any cardiomyopathy or left ventricular ejection fraction <40%, respectively. This supports a role for AI-ECG interpretation of images as a scalable approach for the baseline risk stratification of patients initiating cardiotoxic chemotherapy.

KEY WORDS

Cardiotoxicity, electrocardiography, artificial intelligence, chemotherapy, immunotherapy, cardio-oncology

ABBREVIATIONS LIST

AC: anthracyclines

AI: artificial intelligence

CCS(R): Clinical Classification Software (Refined)

CI: confidence interval

CTRCD: cancer therapeutics-related cardiac dysfunction

ECG: electrocardiography

EHR: electronic health record

GLS: global longitudinal strain

HER2: human epidermal growth factor receptor-2 (HER2) receptor inhibitors

HR: hazard ratio

ICD: International Classification of Diseases

ICI: immune checkpoint inhibitors

IQR: interquartile range

LVSD: left ventricular systolic dysfunction.

INTRODUCTION

Several oncological therapies that have enabled improvements in cancer-specific survival pose long-term deleterious effects on the cardiovascular system.[3] There is an emerging need to design scalable and affordable protocols for the efficient risk stratification of cardiac therapeutics-related cardiac dysfunction (CTRCD), predominantly for patients exposed to widely used chemotherapy and immunotherapy agents, such as anthracyclines,[4] human epidermal growth factor receptor-2 (HER2) receptor inhibitors, or immune checkpoint inhibitors (ICI).[5–7] Recent guideline statements have summarized a growing body of literature on the appropriate risk stratification, prevention, and management of comorbid or incident cardiovascular disease,[3, 8, 9] boosted by the development in non-invasive biomarkers,[10] multimodal imaging,[11] and, more recently, artificial intelligence (AI).[12–15]

Despite this, the accurate identification of high-risk individuals *before* the initiation of therapy remains an elusive goal. A recent systematic review concluded that there is currently insufficient evidence for personalized risk prediction tools in this population.[16] However, trials of screening strategies using advanced echocardiographic indices, such as global longitudinal strain (GLS)[17] have suggested possible benefit from flagging subclinical left ventricular systolic dysfunction and guiding the deployment of potentially disease-modifying therapies.[18–25] Therefore, there is an unmet need to design scalable yet personalized tools to enable the timely identification of patients who might benefit from more intensive follow-up. Furthermore, it is critical that these tools are accessible and affordable, ensuring equitable and broad access across high and low-resource settings.

Building on recent advances in AI-ECG (AI-electrocardiography), a recently developed and validated deep learning model trained against concurrent echocardiographic labels has been

shown to predict both the presence and future risk of left ventricular systolic dysfunction (LVSD) directly from ECG images.[26, 27] This tool, accessible to the end-user on any browser or smartphone interface enables clinicians to screen for LVSD at the point-of-care. In the present study, we first examine the cross-sectional correlation between AI-ECG LVSD predictions and concurrent GLS measurements on transthoracic echocardiography. Next, we hypothesized that AI applied to ECG images of patients undergoing potential cardiotoxic chemotherapy with anthracyclines or trastuzumab may identify individuals at higher risk of CTRCD independent of traditional cardiovascular factors and in the absence of clinical LVSD at the time of treatment initiation. We evaluate the specificity of this association of AI-ECG for future LVSD risk using a negative control analysis of patients on ICI therapy followed for the incidence of myocarditis, an idiosyncratic immune-related adverse event.[5, 6]

METHODS

Data Source and Patient Population

This was a retrospective cohort study of patients who received treatment with anthracyclines, trastuzumab, or ICI between January 1, 2013, and December 5, 2023. We identified all individuals within the electronic health record (EHR) of the Yale-New Haven Health (YNHH) system, a system spanning five hospitals and several clinics across Connecticut and Rhode Island for eligible individuals who were 18 years or older at the time of their treatment to define two distinct cohorts. Our main cohort consisted of adult patients with breast cancer or non-Hodgkin lymphoma who received treatment with anthracycline (doxorubicin, daunorubicin, valrubicin, epirubicin, idarubicin or mitoxantrone), and/or trastuzumab (breast cancer) within five years of their index cancer diagnosis, who were followed for the primary outcome of CTRCD. For a

negative control analysis, we further identified a broad population of adult patients with various forms of cancer undergoing immunotherapy with any combination of ICI (pembrolizumab, ipilimumab, nivolumab, atezolizumab, cemiplimab, avelumab, durvalumab, teremelimumab, relatlimab, toripalimab) who were followed for the primary outcome of myocarditis (**Figure 1**).

To be eligible for inclusion in our analysis, we required the presence of a 12-lead ECG within 36 months before, up to 1 month after treatment initiation. We excluded cases where patients received any of these therapies in the context of a clinical trial, as well as patients who had a history of LVEF <50% and/or a diagnosis of cardiomyopathy or heart failure at baseline. For individuals with two or more cancers, we defined the chronologically first cancer diagnosis and treatment regimen as the index diagnosis and exposure for that participant. Furthermore, to prevent data leakage from our model's training, we excluded all ECGs that were previously used in the training of the image-based AI-ECG model.[26]

Study Covariates

We collected information on demographics (age, sex, race, ethnicity), medications, and diagnoses from the electronic health record (EHR) of the hospital system. We defined all diagnoses, inclusive of cancer type, as well as traditional cardiovascular risk factors and comorbidities (i.e., hypertension, diabetes mellitus, chronic kidney disease, peripheral arterial disease, stroke) using a combination of ICD-9-CM and ICD-10-CM (International Classification of Diseases [ICD] 9 and 10 Clinical Modification) diagnosis codes. ICD codes were mapped to categories defined using CCSR (Clinical Classification Software - Refined) codes, curated and maintained by the AHRQ (Agency for Healthcare Research and Quality) (**Table S1**). Where applicable, diagnoses of ischemic heart disease, and peripheral arterial disease were

supplemented by current procedural terminology (CPT) codes describing disease-defining procedures, such as percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) or carotid or peripheral arterial interventions (**Table S2**). To account for possible delays in administrative claims and recordings, baseline procedure and diagnosis code recorded up before and up to 30 days after treatment initiation.

AI-Guided Stratification Of LVSD Risk On ECG Images

Baseline 12-lead ECG studies were extracted and pre-processed using our previously described pipeline,[26] to create images of ECGs. This approach simulates a clinical workflow where a provider may wish to directly access the algorithm through their browser or smartphone application by taking a photo or screenshot of a 12-lead ECG. We then deployed our previously fine-tuned convolutional neural network (CNN) to obtain a probability of LVSD, ranging from 0 to 1 (with a previously validated cutoff of 0.1 to discriminate positive from negative screens).[26] An online version of the model with an interactive user interface is publicly available for research use at: https://www.cards-lab.org/ecgvision-lv.[28]

Saliency maps

For explainability, we used the GradCAM (Gradient-weighted Class Activation)[29] method to highlight the parts of the image that were the most important in predicting the LVSD class. This is done by calculating the gradients on the final stack of filters in the deep learning model (EfficientNet-B3) architecture for each case, performing a global average pooling of the gradients in each filter, and emphasizing those contributing to the prediction. These are then multiplied by their importance weights and combined across filters to generate GradCAM

heatmaps, as previously reported.[26] GradCAM intensities, from 0 to 1, are converted to a color range using the jet colormap, which is upsampled and overlaid to the original image size with a transparency level of alpha=0.3.

Study Outcomes:

In the imaging correlation analysis, we evaluated the cross-sectional association of AI-ECG based LVSD classification with baseline echocardiography-determined GLS (%), as reported by the cardiologist who interpreted the original study. This analysis was restricted to GLS measurements performed within 15 days (-15 to +15 days) of the respective ECG.

In the clinical outcomes analysis, we evaluated the incidence of CTRCD, which was defined using a combination of diagnosis codes and/or objectively defined left ventricular systolic dysfunction. This included the time-to-first diagnosis of a relevant cardiomyopathy (**Table S1**), left ventricular systolic dysfunction, or heart failure, or an echocardiogram with a post-treatment LVEF below 50%. Secondary outcomes were the time-to-first-LVEF <50%, or <40%, as determined on echocardiography. Of note, given variations in the definitions across different guidelines,[3, 9] as well as the time period of our study, which pre-dated much of the current evidence on the role of GLS,[17, 18] we did not include relative changes in GLS in our outcome.

In the ICI cohort, the primary outcome was the time-to-myocarditis, with death reported as a secondary outcome. Given the multimodal nature of this diagnosis, that often involves multimodality imaging and biomarker assessment integrated with relevant clinical history, symptoms, and clinical exam findings, we opted to define this as the first appearance of a myocarditis-specific ICD/CCS(R) code after treatment. In both cohorts, we also analyzed the

time-to-all-cause mortality, as a secondary outcome. In a secondary analysis, we provided descriptive summaries of AI-ECG LVSD predictions in discrete time intervals leading up to CTRCD diagnosis (or last known follow-up for controls).

Statistical Analysis

Continuous variables are summarized using median (interquartile range; IQR) or mean (standard deviation) values, as appropriate, and categorical variables as counts (percentages, %). For the imaging outcome analyses, the distribution of GLS across subgroups of AI-ECG predictions were summarized using density plots and compared using the non-parametric Kruskal-Wallis test.

We evaluated the AI-ECG LVSD model as a predictor for subsequent CTRCD. This was done using two approaches. First, we compared the association between the binary screening profile (positive if score/probability of AI-ECG LVSD 0.1 or greater, negative if <0.1) with the downstream incidence of the primary and secondary outcomes was assessed in multivariable Cox regression models adjusted for the patient's baseline age, sex, race, and ethnicity, as well as traditional cardiovascular risk factors, including the presence of hypertension, diabetes mellitus, coronary artery disease, peripheral arterial disease, preceding stroke, chronic kidney disease, and smoking. Second, to evaluate the role of AI-ECG in identifying periods leading up to CTRCD, we compared the log-transformed AI-ECG scores across 12-month intervals (48-36, 36-24, 24-12, 12-0 months before CTRCD diagnosis or last known follow-up) between patients with versus without CTRCD using two-way analysis of variance (ANOVA). This was followed by post-hoc pairwise comparisons within each time period between the CTRCD and non-CTRCD groups.

These were performed by independent sample t-tests with alpha adjusted for multiple comparisons using the Bonferroni method.

Across all multivariable regression models covariates with missing values were imputed using non-parametric chained equation imputation with random forests by including all model covariates.[30] All statistical tests were two-sided with a significance level of 0.05. Analyses were performed using Python (version 3.11.2) and R (version 4.2.3).

Ethical Approval: The Yale Institutional Review Board (IRB) approved our study and waived the requirement for informed consent for this retrospective, chart review study.

RESULTS

Summary of the overall patient population

Our initial chart review identified 14,506 unique patients (median age of 67 [IQR 58-76] years, 8,775 (60.5%) women) who received any of the 3 classes of medications between 2013 and 2023 (n=6,176 anthracyclines, n=2,043 trastuzumab, n=6330 ICI), with the most common cancer types including breast cancer (n=4,504), respiratory cancers (n=3,704), Non-Hodgkin lymphomas (n=2,249), and melanoma (n=1,291). The cumulative exposure to one or more classes of therapies across patients with one or more cancer types is summarized in **Figure 1**.

Cross-sectional correlation between AI-ECG and GLS

There were 58,876 and 53,296 ECGs identified in 6,098 and 5,277 patients receiving anthracyclines/trastuzumab or ICI, with 10,801 and 2,880 ECGs performed before or within 30 days of treatment initiation, respectively (**Figure 2**). We identified 7,271 pairs of 12-lead ECGs

and transthoracic echocardiograms with GLS within 15 days of each other among 2,004 unique patients. There was a graded relationship between higher AI-ECG LVSD scores and lower GLS, indicative of worse LV systolic function, with the median [IQR] GLS ranging from -18 [-20 to -17]% for AI-ECG scores <0.1 (n=6333), to -16 [-19 to -13]% for AI-ECG scores ≥0.1 but <0.5 (n=759), and -12 [-15 to -9]% for AI-ECG scores ≥0.5 (n=179) (*p*<0.001) (**Figure 3a**). Of note, this was consistent in a subgroup analysis that only included patients with concurrent LVEF measurements of ≥50% (AI-ECG scores <0.1 (n=6049): GLS -19 [-20 to -17]%, 0.1 to 0.5 (n=536): GLS -17 [-20 to -15]%, and ≥0.5 (n=60): GLS -16 [-19 to -14]%, *p*<0.001) (**Figure 3b**).

AI-ECG and future CTRCD with anthracyclines or trastuzumab

We identified a total of 1,308 patients (age 59 [IQR 49-67] years, 999 [76.4%] women) with breast cancer (n=801, 61.2%) or non-Hodgkin lymphoma (n=560, 42.8%) who had available *baseline* 12-lead ECG within a median of 1 day before [IQR: 29 days before to 1 day after] treatment initiation, and no prior history of cardiomyopathy. More than two in three (n=952, 72.8%) received treatment with doxorubicin, and one in four (n=336, 25.7%) treatment with trastuzumab (**Table 1)**. The median AI-ECG LVSD prediction at baseline was 0.01 [IQR 0.00-0.02], with 81 (6.2%) participants screening positive (≥0.1) for LVSD at baseline. Over a median follow-up of 80 [IQR 42-115] months, there were 404 (30.9%) cases meeting our CTRCD criteria, and 327 (25.0%) deaths. Higher baseline AI-ECG scores were significantly and independently associated with a higher risk of CTRCD (adj. HR 2.22 [95%CI: 1.63-3.02], *p*<0.001) (**Figure 4a**). In a secondary analysis of LVEF-based outcomes, positive AI-ECG screening was associated with a 3.7-fold higher risk of developing an LVEF<50% (n=122

events, $HR_{adjusted}$ 3.66 [95%CI: 2.25-5.94], $p<0.001$), and a 4.8-fold higher risk of developing an LVEF<40% (n=72 events, $HR_{adjusted}$ 4.76 [95%CI: 2.62-8.66], $p<0.001$) (**Figure 4b**). Higher AI-ECG LVSD scores were also predictive of worse overall survival (n=327 deaths, $HR_{adjusted}$ 1.78 [95%CI: 1.26-2.52], $p<0.001$).

Dynamic changes in AI-ECG LVSD predictions prior to CTRCD

When further analyzing the trends in the AI-ECG scores in 12-month intervals leading up to the time of CTRCD (or the last known follow-up for those who did not experience the event), we observed a progressive rise in the AI-ECG scores of the CTRCD group relative to controls, with significant differences noted as early as 12-to-24 months before diagnosis (**Figure 5**). In **Figure 6**, we provide a representative example of a person in their 80s who developed CTRCD after initiating treatment with an anthracycline-based regimen. The initial ECGs were consistent with negative screens (AI-ECG LVSD predictions of 0.001 and 0.014 within 3 and ~6 months of treatment initiation). However, a 12-lead ECG performed approximately 12 months later demonstrated new conduction and ST/T abnormalities, with the AI-ECG model now providing a positive screen with a probability of 0.998, shortly before an echocardiogram confirmed a new reduction in LVEF to <20% from >55% at baseline.

AI-ECG and future myocarditis in patients undergoing treatment with ICI

We identified 2,056 patients who received ICI (age 65 [IQR 57-73] years, 913 (44.4%) women) and had available baseline 12-lead ECG within a median of -1 [-19 to 0] days before treatment initiation, with no prior history of cardiomyopathy. The most common agent was pembrolizumab (n=1055, 51.3%), whereas the most common cancer diagnoses were lung cancer (n=978, 47.6%),

followed by melanoma (n=364, 17.7%). The median AI-ECG LVSD prediction was 0.01 [IQR 0.00-0.03], with 204 (9.9%) of participants screening positive (≥0.1 for LVSD at baseline). Over a median follow-up of 63 [IQR 28-99] months, there were 35 (1.7%) myocarditis cases, and 965 (46.9%) deaths. In a negative control analysis, baseline AI-ECG scores were not associated with the risk of downstream myocarditis ($HR_{adjusted}$ 1.36 [0.47-3.93], p=0.57) (**Figure 7**), or death ($HR_{adjusted}$ 1.15 [0.95-1.41], p=0.16).

DISCUSSION

We demonstrate a validated AI-ECG biomarker that only requires images of ECGs can identify individuals with normal systolic function at baseline and no prior cardiomyopathy who are at increased risk of developing CTRCD following exposure to anthracyclines or trastuzumab. A positive AI-ECG screen at baseline translated into a nearly 2 to 5-fold higher adjusted risk of developing new cardiomyopathy or heart failure during follow-up, independent of the baseline risk profile. Further to the prognostic value of baseline AI-ECG, we provide evidence that across the spectrum of cancer-related cardiotoxicity, AI-ECG predictions exhibit a dynamic course, with a significant increase relative to controls as early as 12-24 months before the clinical diagnosis of anthracycline or trastuzumab-related cardiomyopathy. Collectively, these findings support the use of a validated, accessible, and scalable technology as an additional read-out in guiding the risk stratification of patients referred for potential cardiotoxic chemotherapy.

Our findings supplement a rapidly expanding body of literature in cardio-oncology, as summarized in recently published guidelines and clinical consensus statements.[3, 9] Given its ubiquitous nature and low cost, ECG is widely endorsed as a class I recommendation for the baseline cardiovascular risk stratification before initiating potentially cardiotoxic chemotherapy,

including anthracyclines and/or trastuzumab.[3, 15] Transthoracic echocardiography (TTE),[31] including strain imaging by GLS,[17, 18] and circulating biomarker characterization with natriuretic peptide and troponin measurements,[3, 31–34] are also routinely recommended according to the risk profile of the proposed regimen and each individual patient. More recently, multimodal imaging with magnetic resonance imaging, including T1 mapping, extracellular volume (ECV) quantification,[11, 14] or positron emission tomography with radiotracers tracking myocardial function, metabolism, and tissue repair have also shown value in pre-clinical or small clinical studies.[14, 35, 36] However, access to these technologies varies across different parts of the world,[37–39] underlining an unmet need for efficient cardiovascular risk stratification that can be performed at the point-of-care using readily accessible, yet personalized technologies.

Our work builds on recent developments in the AI-ECG space,[12, 13, 26, 40–42] highlighting the ability of convolutional neural networks and other deep learning architectures to extract features that identify hidden and previously unrecognized labels of cardiovascular disease. However, it is innovative in several key aspects. First, our model, freely available online and directly accessible to any user,[28] enables direct screening for a label that has traditionally required echocardiography, MRI or (MUGA) scans for its accurate quantification.[43] This provides an inexpensive, yet globally available technology for the monitoring and risk stratification of some of the most common forms of cancer and widely used agents in oncology. Second, unlike previously described and validated algorithms that rely on ECG signals,[12, 42] our approach may use any real-world ECG image as input. This enables scalable inference at the point-of-care without requiring local health systems to reconfigure their electronic health record pipelines or establish such systems where they are not available. This directly addresses one of the key goals of medical AI, which is to build solutions that attenuate rather than exacerbate

existing disparities in healthcare access.[44] Finally, our work expands recent reports on the use of signal-based AI-ECG models as diagnostic tools to detect concomitant LVEF reduction detectable on echocardiography, as shown in an analysis of 683 female breast cancer patients who were treated with anthracycline chemotherapy, with an area under the receiver operating characteristic (AUROC) curve of 0.93 for detecting concomitant LVEF of less than 50%.[12] Critically, the present work expands this to baseline risk stratification at treatment initiation, supporting the prognostic and diagnostic value of AI-ECG detection of LVSD. Furthermore, we provide data supporting that AI-ECG predictions may dynamically evolve over the course of the treatment, potentially identifying at risk individuals as early as 12-24 months before clinical diagnosis, findings that stand consistent with longitudinal cohort studies using multimodal imaging.[45–47]

Limitations

Certain limitations merit consideration. First, our study was a retrospective cohort analysis including patients and monitoring practices that predated the most recent cardio-oncology guidelines. As a result, there was variation in the intensity and frequency of cardiovascular monitoring and diagnostic testing. This further limited our ability to integrate circulating biomarkers as additional readouts or covariates in our models. We feel, however, that the present study lays a solid foundation for a prospective clinical trial of ambulatory AI-ECG-enabled monitoring. Second, there are numerous combinations of potentially cardiotoxic agents and cancer types and subtypes, all with different baseline risk profiles and comorbidities, which were impossible to model in the context of this study. Third, we did not account for concomitant medication changes, or additional cancer-directed therapies, such as radiation therapy, which

could potentially impact the cardiovascular profile of these patients. Since such interventions may occur anytime during follow-up or before the start date of these agents, we opted for a descriptive, observational analysis of our cohort and did not model for these time-varying effects.

CONCLUSION

An AI tool that takes ECG images as input offers a robust and scalable solution to identify individuals at high risk of developing CTRCD in response to cardiotoxic chemotherapy. Our findings support the potential utility of AI-ECG monitoring for the cost-effective risk stratification and triage of patients receiving anthracyclines or anti-HER-2 therapies.

PERSPECTIVES:

Core Clinical Competencies:

- Cancer therapeutics may exert cardiotoxic effects that limit their effectiveness. There is an unmet need to efficiently stratify the risk of cancer therapeutics-related cardiac dysfunction (CTRCD) before treatment initiation using personalized approaches.

Translational Outlook Implications:

- Artificial intelligence (AI) applied to electrocardiographic (ECG) images can identify individuals with a 2-to-5-fold higher adjusted risk of developing CTRCD following exposure to anthracyclines or trastuzumab.
- AI-ECG predictions exhibit dynamic trends, with an increase in predictions detected as early as 12 to 24 months before the clinical diagnosis of CTRCD.

REFERENCES

1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA Cancer J Clin*. 2023;73:17–48.

2. Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. *CA Cancer J Clin*. 2022;72:409–436.

3. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J*. 2022;43:4229–4361.

4. Larsen CM, Garcia Arango M, Dasari H, et al. Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010. *JAMA Netw Open*. 2023;6:e2254669.

5. Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. *J Am Heart Assoc*. 2020;9:e013757.

6. Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. *N Engl J Med*. 2016;375:1749–1755.

7. Moslehi Javid, Salem Joe-Elie. Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions. *JACC: CardioOncology*. 2022;4:704–707.

8. Abdel-Qadir H, Austin PC, Lee DS, et al. A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer. *JAMA Cardiol*. 2017;2:88–93.

9. Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. *Eur Heart J*. 2022;43:280–299.

10. Murtagh G, Januzzi JL, Scherrer-Crosbie M, et al. Circulating Cardiovascular Biomarkers in Cancer Therapeutics-Related Cardiotoxicity: Review of Critical Challenges, Solutions, and Future Directions. *J Am Heart Assoc*. 2023;12:e029574.

11. Baldassarre Lauren A., Ganatra Sarju, Lopez-Mattei Juan, et al. Advances in Multimodality Imaging in Cardio-Oncology. *J Am Coll Cardiol*. 2022;80:1560–1578.

12. Jacobs JEJ, Greason G, Mangold KE, et al. Artificial Intelligence ECG as a Novel Screening Tool to Detect a Newly Abnormal Left Ventricular Ejection Fraction After Anthracycline-Based Cancer Therapy. *Eur J Prev Cardiol*. 2023. Published onlineNovember 7, 2023. https://doi.org/10.1093/eurjpc/zwad348.

13. Yao X, Rushlow DR, Inselman JW, et al. Artificial intelligence-enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial. *Nat Med*. 2021;27:815–819.

14. Kwan JM, Oikonomou EK, Henry ML, Sinusas AJ. Multimodality advanced cardiovascular and molecular imaging for early detection and monitoring of cancer therapy-associated cardiotoxicity and the role of artificial intelligence and big data. *Front Cardiovasc Med*. 2022;9:829553.

15. Martinez DS-L, Noseworthy PA, Akbilgic O, et al. Artificial intelligence opportunities in cardio-oncology: Overview with spotlight on electrocardiography. *Am Heart J Plus*. 2022;15.

16. Kaboré EG, Macdonald C, Kaboré A, et al. Risk Prediction Models for Cardiotoxicity of Chemotherapy Among Patients With Breast Cancer: A Systematic Review. *JAMA Netw Open*. 2023;6:e230569.

17. Oikonomou EK, Kokkinidis DG, Kampaktsis PN, et al. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. *JAMA Cardiol*. 2019;4:1007–1018.

18. Thavendiranathan P, Negishi T, Somerset E, et al. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. *J Am Coll Cardiol*. 2021;77:392–401.

19. Henriksen Peter A., Rankin Stephen, Lang Ninian N. Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity. *JACC: CardioOncology*. 2023;5:292–297.

20. Heck SL, Mecinaj A, Ree AH, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. *Circulation*. 2021;143:2431–2440.

21. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. *J Clin Oncol*. 2004;22:820–828.

22. Armenian SH, Hudson MM, Lindenfeld L, et al. Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial. *Lancet Oncol*. 2024;25:235–245.

23. Hundley WG, D'Agostino R Jr, Crotts T, et al. Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment. *NEJM Evid*. 2022;1.

24. Neilan TG, Quinaglia T, Onoue T, et al. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. *JAMA*. 2023;330:528–536.

25. Titus A, Cheema HA, Shafiee A, et al. Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis. *Curr Probl Cardiol*. 2023;48:101885.

26. Sangha V, Nargesi AA, Dhingra LS, et al. Detection of Left Ventricular Systolic Dysfunction From Electrocardiographic Images. *Circulation*. 2023. Published onlineJuly 25, 2023. https://doi.org/10.1161/CIRCULATIONAHA.122.062646.

27. Sangha V, Mortazavi BJ, Haimovich AD, et al. Automated multilabel diagnosis on electrocardiographic images and signals. *Nat Commun*. 2022;13:1583.

28. Anon. ECGVision LV© — Cardiovascular Data Science Lab (CarDS) Lab @ Yale. *Cardiovascular Data Science Lab (CarDS) Lab @ Yale* Accessed February 16, 2024. https://www.cards-lab.org/ecgvision-lv.

29. Selvaraju RR, Cogswell M, Das A, Vedantam R, Parikh D, Batra D. Grad-CAM: Visual Explanations from Deep Networks via Gradient-based Localization. *arXiv [csCV]*. 2016.

30. Stekhoven DJ, Bühlmann P. MissForest--non-parametric missing value imputation for mixed-type data. *Bioinformatics*. 2012;28:112–118.

31. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2014;27:911–939.

32. Michel L, Mincu RI, Mahabadi AA, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. *Eur J Heart Fail*. 2020;22:350–361.

33. de Azambuja E, Ponde N, Procter M, et al. A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. *Breast Cancer Res Treat*. 2020;179:161–171.

34. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. *J Clin Oncol*. 2005;23:7811–7819.

35. Becker MMC, Arruda GFA, Berenguer DRF, Buril RO, Cardinale D, Brandão SCS. Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker. *Cardiooncology*. 2023;9:17.

36. Kelly JM, Babich JW. PET Tracers for Imaging Cardiac Function in Cardio-oncology. *Curr Cardiol Rep*. 2022;24:247–260.

37. Hricak H, Ward ZJ, Atun R, Abdel-Wahab M, Muellner A, Scott AM. Increasing Access to Imaging for Addressing the Global Cancer Epidemic. *Radiology*. 2021;301:543–546.

38. Sierra-Galan LM, Estrada-Lopez EES, Ferrari VA, et al. Worldwide variation in cardiovascular magnetic resonance practice models. *J Cardiovasc Magn Reson*. 2023;25:38.

39. Menacho KD, Ramirez S, Perez A, et al. Improving cardiovascular magnetic resonance access in low- and middle-income countries for cardiomyopathy assessment: rapid cardiovascular magnetic resonance. *Eur Heart J*. 2022;43:2496–2507.

40. Attia ZI, Harmon DM, Behr ER, Friedman PA. Application of artificial intelligence to the electrocardiogram. *Eur Heart J*. 2021;42:4717–4730.

41. Attia ZI, Harmon DM, Dugan J, et al. Prospective evaluation of smartwatch-enabled detection of left ventricular dysfunction. *Nat Med*. 2022;28:2497–2503.

42. Attia ZI, Kapa S, Lopez-Jimenez F, et al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. *Nat Med*. 2019;25:70–74.

43. Printezi MI, Yousif LIE, Kamphuis JAM, et al. LVEF by Multigated Acquisition Scan Compared to Other Imaging Modalities in Cardio-Oncology: a Systematic Review. *Curr Heart Fail Rep*. 2022;19:136–145.

44. Hswen Y, Voelker R. New AI Tools Must Have Health Equity in Their DNA. *JAMA*. 2023;330:1604–1607.

45. Jordan JH, Vasu S, Morgan TM, et al. Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors. *Circ Cardiovasc Imaging*. 2016;9.

46. Tahir E, Azar M, Shihada S, et al. Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT. *Eur Radiol*. 2022;32:1853–1865.

47. Giusca S, Korosoglou G, Montenbruck M, et al. Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up. *Circ Cardiovasc Imaging*. 2021;14:e012459.

Table 1. Table of demographics.

	Cohort #1: Anthracyclines or trastuzumab	Cohort #2: ICI cohort
Total counts	1,308 (100%)	2,056 (100%)
Age (years)	59 [49-67]	65 [57-73]
Female sex	999 (76.4%)	913 (44.4%)
African American/Black Race	160 (12.2%)	202 (9.8%)
Asian Race	23 (1.8%)	32 (1.6%)
White Race	998 (76.3%)	1,700 (82.7%)
Other/Unknown Race	127 (9.7%)	122 (5.9%)
Hispanic Ethnicity	123 (9.4%)	107 (5.2%)
Cancer diagnosis and exposure:		
Cancer diagnosis	Breast cancer (n=801, 61.2%) NHL (n=560, 38.8%)	Lung cancer (n=978, 47.6%) Melanoma (n=364, 17.7%) Other (n=714, 34.7%)
Agent(s) used	Doxorubicin (n=952, 72.8%) Epirubicin (n=23, 1.8%) Mitoxantrone (n=23, 1.8%) Idarubicin (n=35, 2.7%) Daunorubicin (n=33, 2.5%) Trastuzumab (n=336, 25.7%)	Pembrolizumab (n=1,055, 51.3%) Nivolumab (n=707, 34.4%) Atezolizumab (n=199, 9.7%) Avelumab ((n=8, 0.4%) Durvalumab (n=122, 5.9%) Ipilimumab (n=351, 17.1%) Tremelimumab (n=6, 0.3%) Cemiplimab (n=25, 1.2%)
Comorbidities at baseline:		
Prior cardiomyopathy/HF	0 (0%)	0 (0%)
Hypertension	524 (40.1%)	1,107 (53.8%)
Diabetes Mellitus	189 (14.5%)	368 (17.9%)
Ischemic Heart Disease	102 (7.8%)	327 (15.9%)
Stroke/TIA	31 (2.4%)	119 (5.8%)
Peripheral Arterial Disease	46 (4.5%)	156 (7.6%)
Follow-up:		
Follow-up (months)	80 [42-115]	63 [28-99]
Deaths	327 (25.0%)	965 (46.9%)
Primary outcome	CTRCD: 404 (30.9%)	Myocarditis: 35 (1.7%)

CTRCD: cancer therapeutics-related cardiac dysfunction; HF: heart failure; ICI: immune checkpoint inhibitors; TIA: transient ischemic attack. Continuous variables summarized as median [IQR; interquartile range], whereas categorical variables are summarized as n (%).

Figure Titles And Legends



Central Illustration. AI: artificial intelligence; CTRCD: Cancer-therapeutic related cardiac dysfunction; ECG: electrocardiography; LVSD: left ventricular dysfunction.

Figure 1



Figure 1 | Counts of unique patients stratified by cancer types and cumulative exposure to anthracyclines, trastuzumab or ICI. Counts reflect any cancer diagnosis and any exposure during the study period. For instance, an individual participant may have had two or more cancer diagnoses and received different agents for different indication. ICI: immune checkpoint inhibitors.

Figure 2



Figure 2 | Timing of unique ECGs performed relative to the onset of treatment with anthracyclines and/or trastuzumab, or ICI. The plots show histograms of unique ECG counts with the x axis denoting the time difference between the first treatment cycle with anthracyclines and/or trastuzumab (A), and immune ICIs (B). Negative labels reflect ECGs performed before treatment was started. ECG: electrocardiograms; ICI: immune checkpoint inhibitors.

Figure 3



Figure 3 | Distribution of global longitudinal strain (GLS) across AI-ECG LVSD groups. Density polts summarizing GLS across subgroups of AI-ECG LVSD scores (<0.1, 0.1 to <0.5, and 0.5 or greater) for all pairs of ECGs-echocardiograms performed within 15 days of each other (**A,** *n*=6333, 759 and 179, respectively), as well as in a subgroup of echocardiograms with reported LVEF of 50% or greater (**B,** *n*=6049, 536, and 60, respectively). AI: artificial intelligence; ECG: electrocardiography; GLS: global longitudinal strain; LVSD: left ventricular dysfunction.

Figure 4



Figure 4 | Baseline AI-ECG screening for LVSD and incidence of CTRCD among patients receiving anthracyclines/trastuzumab therapy. Kaplan-Meier survival curves for event-free survival and adjusted Cox regression-derived hazard estimates for CTRCD (defined as any LVEF<50%, cardiomyopathy or heart failure) **(A)** or LVEF<40% **(B)** stratified by positive versus negative screening by AI-ECG at baseline. AI: artificial intelligence; CI: confidence interval; CTRCD: Cancer-therapeutic related cardiac dysfunction; ECG: electrocardiography; HR: hazard ratio; LVEF: left ventricular ejection fraction; LVSD: left ventricular dysfunction.

Figure 5



Figure 5 | Evolution in AI-ECG LVSD predictions before CTRCD diagnosis. Means and standard errors of mean (SEM) for the log-transformed AI-ECG LVSD predictions in 12 month intervals leading up to the date of CTRCD diagnosis (or last known follow-up for patients without CTRCD). The comparison of AI-ECG LVSD predictions across groups of patients with CTRCD (orange) vs those without (green) and time was performed using 2-way analysis of variance (ANOVA). Post-hoc comparisons were performed by unpaired t-tests with correction for multiple comparisons using the Bonferroni method. *$p<0.05$, **$p<0.01$. AI: artificial intelligence; CTRCD: Cancer-therapeutic related cardiac dysfunction; ECG: electrocardiography; LVSD: left ventricular dysfunction.

Figure 6



Figure 6 | An example of longitudinal changes in AI-ECG LVSD predictions before CTRCD diagnosis. An example of an octogenarian treated with an anthracycline-based regimen. The figure shows the longitudinal evolution in the 12-lead ECG appearance and the GradCAM (activation/saliency maps) of the AI-ECG LVSD predictions across time, leading up to the diagnosis of CTRCD more than a year following treatment initiation, confirmed by an echocardiographic decline in LVEF to <20% from >55% at baseline. GradCAM visualization of a 12-lead ECG image shortly before the echocardiographic confirmation shows the development of ST-T changes, predominantly in lead V3 and aVL, which largely drive the model's predictions. AI: artificial intelligence; CTRCD: cancer therapeutics-related cardiac dysfunction; ECG: electrocardiography; GradCAM: Gradient-weighted Class Activation; LVEF: left ventricular ejection fraction; LVSD: left ventricular systolic dysfunction.

Figure 7



Positive screen						
At risk	204	165	131	95	54	28
Censored	0	37	71	107	148	172
Events	0	2	2	2	2	4
Negative screen						
At risk	1852	1446	1139	818	521	252
Censored	0	400	700	1015	1307	1571
Events	0	6	13	19	24	29

Figure 7 | Baseline AI-ECG screening for LVSD and incidence of myocarditis among patients receiving ICI therapy. Kaplan-Meier survival curves for event-free survival and adjusted Cox regression-derived hazard estimates for myocarditis stratified by positive versus negative screening by AI-ECG at baseline. AI: artificial intelligence; CI: confidence interval; CTRCD: Cancer-therapeutic related cardiac dysfunction; ECG: electrocardiography; HR: hazard ratio; ICI: immune checkpoint inhibitors.